Drug Search Results
More Filters [+]

MK-8723

Alternative Names: mk-8723, mk8723, mk 8723
Latest Update: 2019-03-15
Latest Update Note: Clinical Trial Update

Product Description

Merck was developing mk-8723, an intravenous agent for Immune Thrombocytopenia Purpura

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-8723

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-8723-001

P1

Completed

Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia

2015-04-26

Recent News Events

Date

Type

Title